Table 2 Recent clinical use of MSCs^a in phase I/II trials

Stroke, 16

Autologous iliac crest

> 90% SH2

DMEM, 10% FCS, Cryo

5 × 10⁷ twice

2 doses, 2-week interval

None

ND

To 5 years

HR for MSCs = 0.344

Con 34%

MSCs 72%

[114]

MI, 10

Autologous iliac crest

CD73+ CD90+ CD105+

DMEM, 10%FCS

7.5 × 10⁶ MSCs + EPCs

1 dose

None

ND

6 months

LVEF 12% up

--

[115]

MI, 53

Allogeneic unmatched 'prochymal'

CD105+ CD166+ CD45^-

Cryo^b

0.5 to 5 × 10⁶/kg

1 dose, intravenous

MSCs 5 pt Placebo 7

ND

6 months

FEV1 up, LVEF up, arrhythmia down

--

[126]

ALS, 10

Autologous iliac crest

CD29+ CD44+ CD90+ CD105+ CD166+

Cambrex

MSC medium 10% FCS

11.4 to 120 × 10⁶

1 dose, thoracic spine

None

ND

4 years

MSCs tolerated, SC scars

--

[116]

ALS, 19 MS, 15

Autologous iliac crest

CD29+ CD73+ CD90+ CD105+ CD166+

DMEM, 10% FCS

ALS 5 × 10⁷ MS 6 × 10⁷ +/- ferumoxide

1 dose, intrathecal; 1 dose, intravenous

None; CD4/25 Treg cells up

Possible

6-25 months

ALSFRS stable, EDSS better

--

[32]

Refractory Crohn's Disease, 10

Autologous iliac crest

CD73+ CD90+ CD105+

DMEM, 10% FCS, Cryo

1 to 2 × 10⁶/kg [mean wt 57 kg, range 46-113 kg

2 doses, 1-week interval

Headache (3 patients) Allergy (1 patient)

ND

14 weeks

CDAI fall (5 patients; > 70 in 3 patients);3 patients worse

--

[117]

Paediatric acute leukaemia 8

Haploid parent BM

Adherent CD phenotype ND

Cryo^b

6 × 10⁴ to 10⁷/kg MSCs + UCBT

1 or 2 doses, 3-week interval

None

None

6.8 years, no chronic GVHD

All patients PMN+ at 9 to 28 days

63%

[109]

Leukaemia 12^c

HLA match opposite gender HCT

CD44+ CD73+ CD90+ CD103+

ND

ND

1 dose

ND

None

0.9-138 months

HCT success, no MSCs took

ND

[110]